ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 1775 • ACR Convergence 2022

    More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)

    Theodore Pincus1, Kathryn Gibson2, Juan Schmukler1, Tengfei Li3 and Joel Block1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Osteoarthritis (OA) patients may have widely divergent scores for pain severity vs X-ray joint damage, indicating that elevated OA pain 0-10 visual numeric scale…
  • Abstract Number: 2090 • ACR Convergence 2022

    Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)

    Alan Cheng1, Vibeke Strand2, Jiandong Su3, Nicole Anderson3, Lee S Simon4 and Zahi Touma3, 1Michael G. DeGroote School of Medicine, McMaster University, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, 2Stanford University School of Medicine, Stanford, CA, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4SDG LLC, West Newton, MA

    Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a novel valid index able to measure disease activity while accounting for prednisone…
  • Abstract Number: 0209 • ACR Convergence 2022

    Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis

    Josh Dan1, Grant Sprow2, Josef Concha3, Nilesh Kodali4, DeAnna Diaz5, Thomas Vazquez6, Felix Chin7, Barbara White8 and Victoria Werth3, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 2Albert Einstein College of Medicine, Philadelphia, PA, 3University of Pennsylvania, Philadelphia, PA, 4New Jersey Medical School, Coppell, TX, 5Philadelphia College of Medicine, Philadelphia, PA, 6FIU Wertheim College of Medicine, Virginia Beach, VA, 7University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 8SFJ Pharmaceuticals, Towson, MD

    Background/Purpose: Variations of the Investigator Global Assessment (IGA) of overall skin disease have been successfully used as a primary efficacy endpoint in registrational clinical trials…
  • Abstract Number: 0402 • ACR Convergence 2022

    Opioid Use and Healthcare Utilization in Adults with PsA and AS

    Alexis Ogdie1, Sofia Pedro2, Jean Liew3 and Kaleb Michaud4, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Boston University, Boston, MA, 4University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Opioid use among individuals with spondyloarthritis is common, reported to be ~20-30% in some cohorts. Data on whether this subset of patients have higher…
  • Abstract Number: 0733 • ACR Convergence 2022

    Median Patient Global Assessment Varies Far More According to FAST4 (fibromyalgia Assessment Screening Tool) and MDS2 (MDHAQ Depression Screen) on a Single MDHAQ (multidimensional Health Assessment Questionnaire) Than According to Primary Diagnosis

    Theodore Pincus1, Kathryn Gibson2, Juan Schmukler1, Tengfei Li3 and Joel Block1, 1Rush University Medical Center, Chicago, IL, 2Liverpool Hospital, Sydney, Australia, 3Georgetown University, Washington, DC

    Background/Purpose: Patient global assessment (PATGL) is a component of DAS28 (disease activity score 28) and CDAI (clinical disease activity index) to assess patients with rheumatoid…
  • Abstract Number: 1137 • ACR Convergence 2022

    MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy

    Kristin Wipfler1, Joshua Baker2 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: MHC class I polypeptide-related sequence A (MICA) is a protein involved in the activation of NK and T cells. Variants within the MICA gene…
  • Abstract Number: 1355 • ACR Convergence 2022

    Relationships Between Work Productivity, Activity Impairment, and Select Patient-Reported Outcomes in Patients with Ankylosing Spondylitis: A Post Hoc Analysis of Two Placebo-Controlled Trials

    Marina Magrey1, James Cheng-Chung WEI2, Arne Yndestad3, Andrew Bushmakin4, Joseph Cappelleri4, Oluwaseyi Dina5 and Atul Deodhar6, 1Case Western Reserve University, University Hospitals, Richfield, OH, 2Chung Shan Medical University Hospital, Taichung, Taiwan, 3Pfizer Inc, Oslo, Norway, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY, 6Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Patients (pts) with AS often experience impaired work productivity.1 In pts with AS receiving tofacitinib (oral Janus kinase inhibitor), improvements were observed in work…
  • Abstract Number: 1785 • ACR Convergence 2022

    PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort

    Susan Bartlett1, orit schieir2, Marie-France Valois2, Janet Pope3, Louis Bessette4, Gilles Boire5, Carol Hitchon6, Edward Keystone7, Carter Thorne8, Diane Tin9, Glen Hazlewood10 and Vivian Bykerk11, 1McGill University, Montreal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3University of Western Ontario, London, ON, Canada, 4Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10University of Calgary, Calgary, AB, Canada, 11Hospital for Special Surgery, New York, NY

    Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
  • Abstract Number: 2094 • ACR Convergence 2022

    Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)

    R. Ezequiel Borgia1, Manuel Ugarte-Gil2, Luis Vilá3, John Reveille4, Gerald McGwin5 and Graciela Alarcón6, 1UH Rainbow Babies & Children's Hospital, Cleveland, OH, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3University of Puerto Rico Medical Sciences Campus, San Juan, PR, 4University of Texas McGovern Medical School, Houston, TX, 5Department of Epidemiology, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL, 6The University of Alabama at Birmingham, Oakland

    Background/Purpose: To examine and compare baseline predictors of improvement in HRQoL in adults with systemic lupus erythematosus (SLE) with disease onset occurring before age 24…
  • Abstract Number: 0210 • ACR Convergence 2022

    Themes in Patients’ Discordance with Provider’s Rheumatoid Arthritis Treatment Goals Relate to Patient Age, Gender, and Ethnicity

    Kelly O'Neill1, Pamela Sinicrope2, Cynthia Crowson3, Kathryne Marks4, Rachel Giblon5, Elena Myasoedova2 and John Davis2, 1Rheumatoid Patient Foundation, Winter Springs, FL, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4Brigham and Women's Hospital, Boston, MA, 5Mayo Clinic, Rochester, MN, Rochester, MN

    Background/Purpose: We previously reported on themes in patients' treatment goals and their association with rheumatoid arthritis (RA) disease activity (DA) and aspects of rheumatology care,…
  • Abstract Number: 0406 • ACR Convergence 2022

    Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?

    Sinead Maguire1, Fiona Wilson2, Phil Gallagher3 and Finbar (Barry) O'Shea1, 1St James' Hospital, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3St Vincent's University Hospital, Dublin, Ireland

    Background/Purpose: The tools to assess disease activity and quality of life in axial spondyloarthritis (axSpA) were developed in ankylosing spondylitis cohorts biased towards inclusion of…
  • Abstract Number: 0735 • ACR Convergence 2022

    Facilitators and Barriers to Weekly Monitoring of Disease Activity with Electronic Patient Reported Outcomes: A Focus Group Study of Patients with Inflammatory Arthritis

    Jim Wiegel1, Bart Seppen2, Michael Nurmohamed3, Marieke ter Wee4 and Wouter Bos1, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Vrije Universiteit | Reade, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands, 4Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands

    Background/Purpose: Telemonitoring disease activity with electronic patient reported outcomes (ePRO's) may reduce the workload of rheumatic care by decreasing outpatient clinic visits. However, low adherence…
  • Abstract Number: 1201 • ACR Convergence 2022

    Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection

    Emily G Oakes1, Jack Ellrodt1, Roberta Alexander2, John Conklin2, May Choi3, Hongshu Guan1, Sara Tedeschi1, Jeffrey Sparks4, Siobhan Case5, Tiffany Hsu1, Daniel Solomon1, Anna Jonsson1 and Karen Costenbader1, 1Brigham and Women's Hospital, Boston, MA, 2Exagen, Inc., Vista, CA, 3Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Brigham and Women's Hospital, Boston Children's Hospital, Boston, MA

    Background/Purpose: Onset of autoimmune connective tissue disease (CTD) after COVID-19 infection has been reported and complement activation has been implicated. We examined common autoimmune rheumatic…
  • Abstract Number: 1357 • ACR Convergence 2022

    The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage

    Annika Maunz1, Joerg Henes2, Joanna Robson3, Johann Jacoby4, Bernhard Hellmich5 and Christian Löffler6, 1Medius Kliniken - Teaching Hospital University of Tübingen, Kirchheim-Teck, Tübingen, Germany, 2Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 3UWE Bristol, Bristol, United Kingdom, 4University Hospital Tübingen, Institute for Clinical Epidemiology and Applied Biometry, Tübingen, Germany, 5Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, 6Medius Kliniken - Teaching Hospital University of Tübingen,, Kirchheim Teck, Germany

    Background/Purpose: The ANCA-associated vasculitis patient-reported outcome (AAV-PRO) is a new disease-specific PRO developed to capture the impact of having AAV and dealing with its treatment…
  • Abstract Number: 1847 • ACR Convergence 2022

    Differences in Key Patient-reported Outcome Domains Identified by the Patient Acceptable Symptom State in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Observational Study (The SAPHO-CNO Study)

    Aleksander Lenert1, Robyn Domsic2, Karmela Kim Chan3, Melissa Oliver4, Jisna Paul5, Courtney Kremer6, Emma Leisinger1, Svjetlana Dolovcak7, Sandy D. Hong8, Aruni Jayatilleke9, Petar Lenert7, T. Shawn Sato1, Samir Shah10, Shima Yasin11, Yongdong (Dan) Zhao12, Daniel Solomon13, Jonathan Templin1 and Polly Ferguson11, 1University of Iowa, Iowa City, IA, 2University of Pittsburgh, Pittsburgh, PA, 3Hospital for Special Surgery, New York, NY, 4Indiana University School of Medicine, Indianapolis, IN, 5Ohio State University Hospital, Dublin, OH, 6University of Iowa Stead Family Children's Hospital, Solna, IA, 7University of Iowa Hospitals and Clinics, Iowa City, IA, 8University of Iowa Stead Family Children's Hospital, Iowa City, IA, 9Temple University, PHILADELPHIA, PA, 10Tufts Medical Center, Boston, MA, 11University of Iowa Carver College of Medicine, Iowa City, IA, 12University of Washington, Redmond, WA, 13Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Incorporating patient perspectives of their disease state is needed for disease activity assessment in adults with SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO). The…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology